IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.

The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease. This study aimed at evaluating the effect of IRC-082451 (base of BN82451), a novel multitargeting hybrid molecule, on L-DOPA-induced dyskinesias...

Full description

Bibliographic Details
Main Authors: Romina Aron Badin, Brigitte Spinnewyn, Marie-Claude Gaillard, Caroline Jan, Carole Malgorn, Nadja Van Camp, Frédéric Dollé, Martine Guillermier, Sabrina Boulet, Anne Bertrand, Marc Savasta, Michel Auguet, Emmanuel Brouillet, Pierre-Etienne Chabrier, Philippe Hantraye
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23300984/?tool=EBI